Technical Analysis for PTCT - PTC Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 37.41 1.27% 0.47
PTCT closed up 1.27 percent on Tuesday, March 19, 2019, on 66 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical PTCT trend table...

Date Alert Name Type % Chg
Mar 19 200 DMA Support Bullish 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Up 3 Days in a Row Strength 0.00%
Mar 19 Up 4 Days in a Row Strength 0.00%
Mar 19 Up 5 Days in a Row Strength 0.00%
Mar 18 Crossed Above 200 DMA Bullish 1.27%
Mar 18 Overbought Stochastic Strength 1.27%
Mar 18 Up 3 Days in a Row Strength 1.27%
Mar 18 Up 4 Days in a Row Strength 1.27%

Older signals for PTCT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases New Jersey Gene Expression Neurological Disorders Celgene Astrazeneca Muscular Dystrophy Spinal Muscular Atrophy Dystrophy Neurodegenerative Disorders Neuromuscular Disorders
Is PTCT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 52.95
52 Week Low 24.6
Average Volume 912,687
200-Day Moving Average 36.9107
50-Day Moving Average 32.904
20-Day Moving Average 34.4785
10-Day Moving Average 35.118
Average True Range 1.4714
ADX 21.25
+DI 31.2881
-DI 13.5107
Chandelier Exit (Long, 3 ATRs ) 33.6158
Chandelier Exit (Short, 3 ATRs ) 33.4742
Upper Bollinger Band 37.5336
Lower Bollinger Band 31.4234
Percent B (%b) 0.98
BandWidth 17.721769
MACD Line 1.194
MACD Signal Line 0.9068
MACD Histogram 0.2872
Fundamentals Value
Market Cap 1.55 Billion
Num Shares 41.4 Million
EPS -3.05
Price-to-Earnings (P/E) Ratio -12.27
Price-to-Sales 5.48
Price-to-Book 3.95
PEG Ratio 0.73
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.32
Resistance 3 (R3) 39.13 38.30 39.00
Resistance 2 (R2) 38.30 37.82 38.40 38.89
Resistance 1 (R1) 37.86 37.52 38.08 38.05 38.79
Pivot Point 37.03 37.03 37.15 37.13 37.03
Support 1 (S1) 36.59 36.55 36.81 36.78 36.03
Support 2 (S2) 35.76 36.25 35.86 35.93
Support 3 (S3) 35.32 35.76 35.82
Support 4 (S4) 35.51